



Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/715,912
Filing Date	November 18, 2003
First Named Inventor	Hinz
Art Unit	4616 1617
Examiner Name	Lamm, M.
Attorney Docket Number	3364.31US08

Sheet

1

of

1

U.S. PATENT DOCUMENTS

EXAMINER INITIAL*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number-Kind Code ² (if known)		
u		US-5,502,080	03-26-1996	Hitzig
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			

EXAMINER
SIGNATURE

DATE

CONSIDERED

7/12/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

Substitute for form 1449/PTO <div style="border: 1px solid black; border-radius: 50%; padding: 10px; width: 100px; float: left; margin-right: 10px;"> INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) MAY 12 2006 </div>			Complete if Known	
			Application Number	10/715,912
			Filing Date	November 18, 2003
			First Named Inventor	Hinz
			Art Unit	1616 1617
			Examiner Name	Lamm, M.
			Attorney Docket Number	3364.31US08

U.S. PATENT DOCUMENTS				
EXAMINER INITIAL*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number-Kind Code ² (if known)		
uu		US-5,977,076	11-02-1999	Anderson
uu		US-6,132,724	10-17-2000	Blum
uu		US-11/282,965	11-18-2005	Hinz
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		

FOREIGN PATENT DOCUMENTS					
EXAMINER INITIAL*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			

EXAMINER SIGNATURE	DATE CONSIDERED	7/12/06
--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

Substitute for form 1449/PTO				Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/715,912	
				Filing Date	November 18, 2003	
				First Named Inventor	Hinz	
				Art Unit	4616 / 617	
				Examiner Name	Lamm, M.	
Sheet <u>1</u> of <u>5</u>				Attorney Docket Number	3364.31US08	
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		
		Number-Kind Code ² (if known)				
u		US-4,397,866	08-09-1983	Wurtman		
		US-5,650,438	07-22-1997	Meier et al.		
		US-2001/0002269	05-31-2001	Zhao		
		US-6,261,589	07-17-2001	Pearson et al.		
		US-2001/0008641	07-19-2001	Krotzer		
		US-2001/0008884	07-19-2001	Worsley		
		US-2001/0020007	09-06-2001	Wiss		
		US-2002/0040054	04-04-2002	Hinz		
		US-6,403,657	06-11-2002	Hinz		
		US-2002/0147206	10-10-2002	Howard, Jr.		
		US-2002/0187958	12-12-2002	Horrobin et al.		
		US-2003/0181509	09-25-2003	Hinz		
		US-6,660,777	12-09-2003	Hinz		
		US-2004/0071681	04-15-2004	Muller		
		US-2004/0077556	04-22-2004	Chinery		
	US-2004/0081678	04-29-2004	Cincotta			
u		US-2004/0101575	05-27-2004	Hinz		
FOREIGN PATENT DOCUMENTS						
EXAMINER INITIAL*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
u		JP 410067663	03-10-1998	Nickolson		
u		WO 01/26642	04-19-2001	Bechthold et al.		
EXAMINER SIGNATURE		DATE CONSIDERED		7/12/06		
<small> *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450. </small>						


Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/715,912
				Filing Date	November 18, 2003
				First Named Inventor	Hinz
				Art Unit	1616 16 17
Examiner Name	Lamm, M.				
Sheet	2	of	5	Attorney Docket Number	3364.31US08

U.S. PATENT DOCUMENTS

EXAMINER INITIAL [*]	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number-Kind Code ² (if known)		
ll		US-2004/0116351	06-17-2004	Halevic-Goldman
		US-2004/0151771	08-05-2004	Gin et al.
		US-2004/0229285	11-18-2004	Hinz
		US-2004/0247669	12-09-2004	Gin et al.
		US-2005/0065190	03-24-2005	Hinz
		US-2005/0233008	10-20-2005	Hinz
		US-2005/0233014	10-20-2005	Lee et al.
		US-2005/0287226	12-29-2005	Sisco et al.
		US-09/523,114	03-10-2000	Hinz
		US-11/353,644	02-14-2006	Hinz
ll		US-11/353,643	02-14-2006	Hinz
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL [*]	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			

EXAMINER SIGNATURE		DATE CONSIDERED	7/12/06
-----------------------	---	--------------------	---------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/715,912
				Filing Date	November 18, 2003
				First Named Inventor	Hinz
				Art Unit	16164/7
				Examiner Name	Lamm, M.
Sheet	3	of	5	Attorney Docket Number 3364.31US08	
NON PATENT LITERATURE DOCUMENTS					
EXAMINER INITIAL*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
u		AGÜNDEZ ET AL., "Modulation of CyP1A2 enzyme activity by indoleamines: inhibition by serotonin and tryptamine", <u>Pharmacogenetics</u> , 8:251-258 (1998).			
f		ANDREWS ET AL., "The Effects of 5-hydroxytryptophan and 5-hydroxytryptamine on Dopamine Synthesis and Release in Rat Brain Striatal Synaptosomes", <u>Journal of Neurochemistry</u> , 30:465-470 (1978).			
		AVARELLO, "Serotonin Syndrome: a reported case", <u>Neuro Sci</u> , 23:S55-S56 (2002).			
		BARTHOLOME ET AL., "L-dopa and 5-hydroxytryptophan Therapy in Phenylalanine-Hydroxylase Activity", <u>The Lancet</u> 2(Nov. 22): 1042-1043 (1975).			
		BOUYER ET AL., "Modification of Spontaneous ECoG and Behavior in Cat by Monoamine Precursors", <u>Psychopharmacology</u> , 65:49-54 (1979).			
		COPPEN ET AL. "Levodopa and L-tryptophan Therapy in Parkinsonism", <u>The Lancet</u> , March 25, (1972).			
		DUNNER ET AL., "Affective Disorder: Studeis with Amine Precursors", <u>Am J. Psychiatry</u> , 132(2):180-183 (1975).			
		GELENBERG ET AL. "Tyrosine for the treatment of depression", <u>Nutr. Health</u> , 3(3):163-73 (1984).			
		HURLEY ET AL., "Pyrrolo[1,4]benzodiazepine Antibiotics. Biosynthesis of the Antitumr Antibiotic 11-Demethyltomaymycin and its Biologically Inactive metaboly Oxotomaymycin to Streptomyces achromogene, <u>Biochemistry</u> , 15(17):3760-3769 (1976).			
u		KRAMARCY ET AL, "Effects of Drug-Inducted Changes in Brian Monoamines on Aggression and Motor Behavior in Mice", <u>European Journal of Pharmacology</u> , 99:141-151 (1984).			
EXAMINER SIGNATURE		DATE CONSIDERED		7/12/06	
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.</p> <p>This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.</p> <p style="text-align: center;"><i>If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.</i></p>					

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/715,912
				Filing Date	November 18, 2003
				First Named Inventor	Hinz
				Art Unit	1616 1617
Examiner Name	Lamm, M.				
Sheet	4	of	5	Attorney Docket Number	3364.31US08
NON PATENT LITERATURE DOCUMENTS					
EXAMINER INITIAL ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
u		LI KAM WA ET AL., "Renal metabolism and effects of the glutamyl derivatives of L-dopa and 5-dihydroxytryptophan in man", <u>Clinical Science</u> , 91:177-185 (1996).			
		LINDSTRÖM ET AL., "Aromatic amino acids and pancreatic islet function: a comparison of L-tryptophan and L-5-hydroxytryptophan", <u>Molecular and Cellular Endocrinology</u> , 48:121-126 (1986).			
		LINDSTRÖM, "Aromatic-L-Amino-Acid Decarboxylase Activity in Mouse Pancreatic Islets", <u>Biochimica et Biophysica Acta</u> , 884: 276-281 (1986).			
		MALONE ET AL., "Treatment (Rx) of 76 Patients with Primary Fibromyalgia (1° FM) with Combined Dopaminergic and Serotonergic Drugs", <u>Arthritis & Rheumatism</u> , 39:S92 (1996) (Abstract).			
		MATHIAU ET AL., "Absence of Serotonergic Innervation from Raphe Nuclei in Rat Cerebral Blood Vessels - II. Lack of Tryptophan Hydroxylase Activity <i>In Vitro</i> " <u>Neuroscience</u> , 52(3): 657-665 (1993).			
		MEYERS, "Use of Neurotransmitter Precursors for Treatment of Depression", <u>Alternative Medicine Review</u> , 5(1):64-71 (2000).			
		NIEDENS ET AL., "First fungal aromatic L-amino acid decarboxylase from a paclitaxel-producing <i>Penicillium raistrickii</i> ", <u>Mycologia</u> , 91(4):61-26 (1999) (Abstract).			
u		RABEY ET AL., "L-tryptophan Administration in L-Dopa-Induced Hallucinations in Elderly Parkinsonian Patients" <u>Gerontology</u> , 23:438-444 (1977).			
EXAMINER SIGNATURE		DATE CONSIDERED		7/12/06	
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.</p> <p>This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.</p> <p style="text-align: center;"><i>If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.</i></p>					

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/715,912
				Filing Date	November 18, 2003
				First Named Inventor	Hinz
				Art Unit	1616 1617
				Examiner Name	Lamm, M.
Sheet	5	of	5	Attorney Docket Number	3364.31US08
NON PATENT LITERATURE DOCUMENTS					
EXAMINER INITIAL ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
uu		SAWAKI ET AL., "Some correlations between Procaine-Induces Convulsions and Monamines in the Spinal Cord of Rats", Japan, J. Pharmacol, 51:369-376 (1989).			
		SCHLOSBERG ET AL., "Effects of L-Dopa and L-5-Hydroxytryptophan on Locomotor Activity of the Rat after Selective or combined destruction of Central Catecholamine and Serotonin Neurons", The Journal of Pharmacology and Experimental Therapeutics, 211(2):296-304 (1979).			
		SHINTAKU ET AL., "Diagnosis and treatment of 6-pyruvoyl-tetrahydropterin synthase deficiency", Brain & Development, 22:S118-S121 (2000).			
		STERNBERG ET AL., "Development of Scleroderma-like Illness during Therapy with L-5-hydroxytryptophan and Carbidopa", The New England Journal of Medicine, 303(14):782-787 (1980).			
		TANAKA ET AL., "Hyperphenylalaninemia Due to Impaired Dihydrobiopterin Biosynthesis", Eur. J. Pediatr, 136:275-280 (1981).			
		THURMOND ET AL., "Effects of Dietary Tyrosine, Phenylalanine, and Tryptophan on Aggression in Mice", Pharmacology Biochemistry & Behavior, 6:475-478 (1977).			
		TRULSON ET AL., "Behavioral Effects of Serotonergic and Dopaminergic Drugs in Cats Following Chronic Amphetamine Administration", European Journal of Pharmacology, 99:313-324 (1984).			
		WEITBRECHT AND ET AL., "Der Einfluss von L-Tryptophan auf die L-Dopa-Resorption", Dtsch Med Wochenschr, 101(1): 20-22 (1976).			
uu		Dave Peterson Affidavit (04/11/2005).			
EXAMINER SIGNATURE		DATE CONSIDERED		7/12/06	
<p>*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.</p> <p>This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.</p> <p style="text-align: center;">If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.</p>					